UNITED STATESTable of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Pursuant to~~Date ~~Section~~of 13Report ~~or 15~~(d)Date of ~~the~~earliest ~~Securities~~event ~~Exchange~~reported) ~~Act~~June 7, ~~of 1934~~2007

~~Date of Report~~LEINER ~~(Date~~HEALTH ofPRODUCTS ~~earliest event reported) March~~INC. ~~22, 2007~~

~~LEINER HEALTH PRODUCTS INC.~~ (Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation or organization) 333-33121 (Commission File Number) 95-3431709 (IRS Employer Identification Number)


DELAWARE (State or other jurisdiction of incorporation or organization)	333-33121 (Commission File Number)	95-3431709 (IRS Employer Identification Number)

901 East 233rd Street, Carson, California (Address of principal executive offices)		90745 (Zip Code)

901 East 233rd Street, Carson, California	90745
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (310) 835-8400

~~Registrant’s telephone number, including area code (310) 835-8400~~N/A

~~N/A~~ (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~o Soliciting~~TABLE ~~material~~OF ~~pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)~~CONTENTS

~~o Pre-commencement~~Item ~~communications~~2.05 ~~pursuant to~~Costs ~~Rule~~Associated ~~14d-2(b)~~with ~~under~~Exit ~~the~~or ~~Exchange~~Disposal ~~Act~~Activities ~~(17~~Item ~~CFR~~8.01 ~~240~~Other Events Item 9.~~14d-2(b))~~01 Financial Statements and Exhibits SIGNATURE EXHIBIT 99.1

o Pre-commencementTable communicationsof pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))Contents

-Item 2.05 Costs Associated with Exit or Disposal Activities. ~~1 -~~

~~Item~~ On June 7, 2007, Leiner Health Products Inc. (the “Company”) announced a plan to consolidate 8its manufacturing and packaging operations.01 ~~Other~~The ~~Events~~consolidation plan calls for the consolidation of the Company’s Fort Mill, South Carolina manufacturing and packaging operation into other Company facilities. Although the Fort Mill facility will continue to distribute products to customers, Fort Mill manufacturing assignments will be transitioned to the Company’s Wilson, North Carolina and Garden Grove, California facilities, and the Fort Mill packaging operations will be transitioned to the Company’s Carson, California facility. The Company will continue to manufacture over-the-counter (“OTC”) products in its Wilson, North Carolina facility. The consolidation will result in the elimination of approximately 540 employee positions and is expected to be completed by September 30, 2007. This consolidation plan is designed to align the Company’s operating expenses with management’s revenue expectation for fiscal years 2008 and 2009, which have been revised following recent events affecting the Company’s OTC business. The Company reaffirmed its commitment to ensuring alignment with the Food and Drug Administration as it moves to resume OTC production and distribution.

~~Our principal~~ The ~~operating~~Company ~~subsidiary,~~estimates ~~Leiner~~that ~~Health~~it ~~Products~~will ~~LLC (the “Company”)~~record, ~~received~~ ain ~~list~~accordance ofwith ~~Inspection~~FASB ~~Observations~~Statement onof ~~Form~~Financial Accounting ~~483~~Standards ~~(the~~No. 146, ~~“Form~~Accounting ~~483”)~~for ~~from~~Costs Associated ~~Food~~with ~~and~~Exit ~~Drug~~or ~~Administration~~Disposal Activities (~~“FDA”)~~SFAS ~~inspectors on March 16~~No. 146), ~~2007.~~total ~~The~~charges ~~Form~~of ~~483 contained~~approximately ~~inspection~~$ ~~observations~~22.0 ~~relating~~ to ~~product~~$ ~~quality~~27.0 million ~~and deficiencies~~ in ~~the~~connection ~~Company’s compliance~~ with ~~good manufacturing practices (“GMP”) for over-~~the~~-counter~~ consolidation ~~drug~~of ~~products~~its ~~(“OTC~~manufacturing ~~Products”)~~and ~~manufactured,~~packaging ~~packaged or tested at its Fort Mill~~operations, ~~South~~consisting ~~Carolina facility.~~ of:

~~The Company~~• ~~believes~~asset ~~that~~relocation ~~its~~and ~~OTC~~related ~~Products~~costs doof ~~not~~approximately ~~pose~~$ ~~any safety issues~~5. ~~Nevertheless,~~0 ~~the Company has implemented several steps~~ to ~~address~~$ ~~the observations described in the Form 483 and assure the integrity of its quality processes and OTC Products~~6.0 Onmillion, ~~March~~• 20severance, ~~2007,~~relocation ~~the~~and ~~Company~~other ~~voluntarily~~employee ~~suspended the~~related ~~production~~costs ~~and distribution~~ of ~~all~~approximately ~~OTC~~$ ~~Products manufactured, packaged or tested at its facilities in the United States~~9.0 ~~The Company is retesting, on a lot-by-lot basis, the retained samples of all unexpired OTC Products previously manufactured, packaged or tested at its US facilities~~ to ~~ensure~~$ ~~that its OTC Products meet quality specifications throughout their shelf-life~~11.0 ~~If any batches do not meet such specifications~~million, ~~the~~and ~~Company~~• ~~intends~~facility toconsolidation ~~take~~and ~~all~~other ~~necessary action.~~contractual ~~Finally,~~costs ~~the~~of ~~Company~~approximately is$ ~~working with Lachman Consultant Services, Inc~~8.~~, a~~0 ~~respected GMP consulting firm,~~ to ~~assure~~$ ~~that~~10.0 ~~future production of OTC Products will be manufactured and tested in accordance with appropriate GMP and product quality standards~~million.

~~As we believe~~ The ~~these~~Company ~~actions~~estimates ~~demonstrate,~~that all of the ~~Company~~above ischarges ~~committed~~will tobe ~~maintaining its core~~incurred ~~values~~as ~~and~~future tocash expenditures. ~~working~~In ~~with~~addition, the ~~FDA~~Company expects to ~~resolve~~spend ~~the~~$4.0 ~~issues~~to ~~raised~~$5.0 million byon ~~the~~leasehold ~~observations~~improvements asto ~~quickly~~accommodate asequipment ~~possible.~~movement ~~However,~~which ~~the~~will ~~Company~~be iscapitalized ~~not~~during ~~yet~~fiscal ~~able~~year to2008. ~~estimate~~Also, ~~how~~the ~~long~~Company it will ~~take~~record toa ~~resolve~~non-cash ~~such~~expense ~~issues.~~related Ifto the ~~observations~~ write down of certain assets in the fourth ~~Form~~quarter ~~483~~of ~~cannot~~its befiscal ~~addressed~~year in2007 as a ~~timely~~result ~~manner~~of atcertain aevents ~~reasonable~~leading ~~cost,~~up itto the OTC ~~may have~~manufacturing ainterruption ~~material~~referenced ~~adverse~~herein. ~~effect~~This onnon-cash ~~our~~write-down ~~results~~expense ofwill ~~operations~~be orincluded ~~financial~~in ~~condition~~the Company’s Annual Report on Form 10-K.

The Company’s ~~vitamin,~~believes ~~mineral~~that the alignment of capacity and ~~supplements~~cost ~~products~~structure ~~were~~with ~~not~~the ~~addressed~~Company’s expected product mix and revenue stream is in the best interests of its constituents. These ~~Form~~changes ~~483~~to ~~and~~the Company’s OTC business are ~~not~~intended ~~included~~to inenable the ~~voluntary~~Company ~~suspension~~to ~~described~~emerge as a quality, ~~above~~highly competitive OTC supplier.

A copy of the Company’s press release, dated June 7, 2007, announcing the consolidation plan is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference 2herein. -

~~SIGNATURE~~- 2 -

Pursuant toTable the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.Contents

~~Leiner~~ Forward-Looking ~~Health Products Inc. By: /s/ Robert K. Reynolds Robert K. Reynolds Chief Operating Officer~~Statements

~~Date:~~ This Current Report on Form 8-K contains forward-looking statements that are subject to risks ~~March~~and 22uncertainties. These statements are indicated by words such as “may,” ~~2007~~“will,” “could,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of such terms or similar expressions. In particular, this Current Report on Form 8-K contains forward-looking statements about management estimates of the charges expected to be incurred with the consolidation of certain manufacturing and packaging operations and the nature of charges to be incurred. These statements are based upon information available to management as of the date hereof. Actual results may differ materially from the anticipated results because of certain risks and uncertainties, including, but not limited to, higher than expected consolidation expenses, a delay in implementation of the consolidation and other risks and uncertainties. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, except as required by law. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by such cautionary statements.

-Item 8.01 Other Events. ~~3 -~~

Conference Call Information

The Company will hold a conference call to discuss the matters raised in this Current Report on Form 8-K on Friday, June 8, 2007, at 11:00 a.m. Eastern Time. The dial-in number for the conference call is 877-278-2335. For those who cannot listen to the live broadcast, a telephone replay of the call will be available from June 8, 2007, at 2:00 p.m. Eastern Time through June 15, 2007, and can be accessed by dialing 800-642-1687, conference ID # 3601478.

Item 9.01 Financial Statements and Exhibits

99.1 Press Release dated June 7, 2007.

The information in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically incorporated by reference in a future filing under such Acts.

- 3 -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Leiner Health Products Inc.
	By:	/s/ Tae J. Rhee

		Tae J. Rhee Senior Vice President and General Counsel

Date June 7, 2007

- 4 -

EXHIBIT INDEX


Exhibit No.		Description

99.1		Press Release dated June 7, 2007.

- 5 -

Filing Compare · LEINER HEALTH PRODUCTS INC